Epidemiological evaluation and survival of children with acute myeloid leukemia

Objective: This study aims to describe the epidemiological characteristics and survival rates of children with acute myeloid leukemia treated in hospitals in southern Brazil and compare them with international data. Methods: A multicenter cohort study was conducted with retrospective data collection of all new patients with acute myeloid leukemia under 18 treated at five referral centers in pediatric hematology-oncology in southern Brazil between January 2005 and December 2015. Results: Of the 149 patients with acute myeloid leukemia, 63.0% (n = 94) were male. The median age at diagnosis was 10.5 years (range 0-18 years) and 40.3% (n = 60) had a white blood cell count below 50,000/mm(2). The most common Franco-American-British (FAB) subtype was M3 (n = 43, 28.9%). Nine (6.0%) patients had central nervous system disease. In M3 patients, overall survival (OS) was 69.2% and 3-year event-free survival was 67.7%; in non-M3 patients, these rates were 45.3% and 36.7%, respectively. In non-M3 patients, OS was significantly different between transplanted (61.8%) and non-transplanted (38.2%) patients (p = 0.031). Conclusions: These results show a higher prevalence of the Franco-American -British M3 subtype than that reported in the international literature, as welt as a decreased OS compared with that of developed countries. Further multicenter Brazilian studies with a larger sample size are encouraged to better understand the characteristics of acute myeloid leukemia, and to improve the treatment and prognosis in this population. (C) 2020 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.

Automated summary

By analyzing data of children with acute myeloid leukemia treated in hospitals in southern Brazil, it was found that the prevalence of the M3 subtype was higher than reported in international literature, and the survival rates were lower compared to developed countries. This study suggests the need for further multicenter Brazilian studies with larger sample sizes to improve the treatment and prognosis in this population.